We observed an upregulation of programed necrosis-related proteins MLKL/RIPK3 and a concomitant downregulation of RIPK1 expression in glioma cell lines U251, U87, A172, and T98G, as well as in an in vivo subcutaneous tumor model, following Shikonin interventions. This evidence concerns the gene RIPK3 and neoplasm.